Cardiovascular magnetic resonance for amyloidosis

Heart Failure Reviews

Volumn 20, Issue 2, 2015, Pages 133-144

  Fontana, Marianna ^a,b   Chung, Robin ^a   Hawkins, Philip N ^b   Moon, James C ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloidosis; CMR; T1 mapping

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GADOLINIUM; TROPONIN; BIOLOGICAL MARKER; CONTRAST MEDIUM;

ARTICLE; BONE SCINTISCANNING; CARDIOVASCULAR MAGNETIC RESONANCE; CELL LOSS; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIASTOLE; DISEASE CLASSIFICATION; DRUG DEVELOPMENT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEALTH CARE DELIVERY; HEALTH SERVICE; HEART AMYLOIDOSIS; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SYSTOLE; TISSUE STRUCTURE; AMYLOIDOSIS; BLOOD; CARDIOMYOPATHY; HEART MUSCLE; HEART STROKE VOLUME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

AMYLOIDOSIS; BIOMARKERS; CARDIOMYOPATHIES; CONTRAST MEDIA; ECHOCARDIOGRAPHY; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; STROKE VOLUME; TROPONIN;

EID: 84928411449     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-014-9470-7     Document Type: Article

References (42)

1. Falk RH, Comenzo RL, Skinner M (1997) The systemic amyloidoses. N Engl J Med 337(13):898–909
2. Meier-Ewert HK, Sanchorawala V, Berk JL, Ruberg FL (2011) Cardiac amyloidosis: evolving approach to diagnosis and management. Curr Treat Options Cardiovasc Med 13(6):528–542. doi:10.1007/s11936-011-0147-4
3. Audet A, Cote N, Couture C, Bosse Y, Despres JP, Pibarot P, Mathieu P (2012) Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology 61(4):610–619. doi:10.1111/j.1365-2559.2012.04265.x
4. Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A (2002) Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 106(16):2091–2097
5. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RMT, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203–1212
6. Pozo E, Kanwar A, Deochand R, Castellano J, Naib T, Pazos-Lopez P, Osman K, Cham M, Narula J, Fuster V, Sanz J (2014) Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. Heart epub 2014 Jul 10
7. Bogaert J, Taylor AM (2005) Non-ischemic myocardial disease. In: Bogaert JDS, Taylor AM (eds) Clinical cardiac MRI. Springer, New York, pp 234–237
8. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH (2014) Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 129(18):1840–1849. doi:10.1161/CIRCULATIONAHA.113.006242
9. White SK, Sado D, Fontana M, Banypersad SM, Maestrini V, Flett AS, Piechnik SK, Robson MD, Hausenloy DJ, Sheikh AM, Hawkins PN, Moon JC (2013) T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging 6:955–962
10. Maceira AM, Joshi J, Prasad SK, Moon J, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:186–193
11. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3:155–164
12. Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO, Starling RC, Desai MY (2009) Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2:1369–1377
13. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103:544–549
14. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51:1022–1030
15. Aquaro GD, Pugliese NR, Perfetto F, Cappelli F, Barison A, Masci PG, Passino C, Emdin M (2014) Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. Int J Cardiovasc Imaging 30(6):1105–1115. doi:10.1007/s10554-014-0436-6
16. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ (2014) CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 7:133–142
17. Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Non-invasive Etiologic diagnosis of cardiac amyloidosis using 99mTC-3,3-Diphophono-1,2-Propanodicarboxylic acid scintography. J Am Coll Cardiol 46:1076–1084
18. Kellman P, Arai AE, McVeigh ER, Aletras AH (2002) Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med 47:372–383
19. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, Piechnik SK, Neubauer S, Roberts N, Moon J (2012) Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson 14:88
20. Kellman P, Hansen M (2014) T1-mapping in the heart: accuracy and precision. J Cardiovasc Magn Reson 16(1):2–20
21. Sado DM, Maestrini V, Piechnik SK, Banypersad SM, White SK, Flett AS, Robson MD, Neubauer S, Ariti C, Arai AE, Kellman P, Yamamura J, Schoennagel BP, Shah F, Davis B, Trompeter S, Walker M, Porter J, Moon JC (2014) Noncontrast myocardial T(1) mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging epub 2014 Aug 8
22. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel TA, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes DA, Neubauer S, Elliott PM, Moon JC (2013) Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 6:392–398
23. Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, Oudit GY (2013) T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 6:637–645
24. Banypersad SM, Sado DN, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC (2013) Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 6:34–39
25. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7:157–165
26. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 6:488–497
27. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB (2013) Society for cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 15(1):92
28. Lee JJ, Liu S, Nacif MS, Ugander M, Han J, Kawel N, Sibley CT, Kellman P, Arai AE, Bluemke DA (2011) Myocardial T1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson 13:75–85
29. Roujol S, Weingärtner S, Foppa M, Chow K, Kawaji K, Ngo LH, Kellman P, Manning WJ, Thompson RB, Nezafat R (2014) Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology 4(4):140296
30. Fontana M, Banypersad S, Treibel TA, Maestrini V, Sado DN, White SK, Bulluck H, Herrey AS, Hawkins PN, Moon JC (2014) AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology. J Cardiovasc Magn Reson 16(Suppl 1):P341
31. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY (2012) Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging 5(9):897–907. doi:10.1016/j.jcmg.2012.04.006
32. Quarta CC, Guldalotti PL, Longhi S, Pettinato C, Leone O, Felrini A, Blagini E, Grigioni F, Bacchi-Reggiani ML, Lorenzini M, Milandri A, Branzi A, Rapezzi C (2012) Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. J Am Coll Cardiol Imaging 5:755–758
33. Koyama J, Falk RH (2010) Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 3:333–342
34. Palka P, Lange A, Fleming AD, Donnelly JE, Dutka DP, Starkey IR, Shaw TR, Sutherland GR, Fox KA (1997) Differences in myocardial velocity gradient measured throughout the cardiac cycle in patients with hypertrophic cardiomyopathy, athletes and patients with left ventricular hypertrophy due to hypertension. J Am Coll Cardiol 30:760–768
35. Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F, Lorenzini M, Terzi F, Bacchi-Reggiani L, Boriani G, Branzi A, Boni L, Rapezzi C (2009) Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol 104:1727–1731
36. Kwong RY, Falk RH (2005) Cardioavascular magnetic resonance in cardiac amyloidosis. Circulation 111:122–124
37. White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, Al-Jaroudi W, Parker M, Patel M, Gwadry-Sridhar F, Judd RM, Kim RJ (2014) CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 7:143–156
38. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad S, Maestrini V, Lane T, Lachmann HJ, Whelan CJ, Wechalekar AD, Manisty C, Herrey AS, Gillmore JD, Hawkins PN, Moon JC (2014) Cardiovascular magnetic resonance in cardiac amyloidosis: a 242 patient prospective study. Am Heart Assoc Sci Sess Abstract accepted
39. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC (2014) T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. doi:10.1093/eurheartj/ehu444
40. Alnylam (2013) Phase 2 study to evaluate ALN-TTRSC in patients with transthyretin (TTR) cardiac amyloidosis. http://www.clinicaltrials.gov/ct2/show/NCT01981837?term=alnylam&rank=2
41. GlaxoSmithKline (2013) A study to evaluate the safety of GSK2398852 when co-administered with GSK2315698 in patients with systemic amyloidosis. http://clinicaltrials.gov/show/NCT01777243
42. Leone O, Longhi S, Quarta C, Ragazzini T, De Giorgi L, Pasquale F, Potena L, Lovato L, Milandri A, Arpesella G, Rapezzi C (2012) New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. Amyloid 19:99–105